Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
- DOI
- 10.1186/s12885-023-10727-3
- Published
- 2024-07-25
- Container
- BMC Cancer
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12885-023-10727-3,
title = {Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study},
author = {Andrea Necchi and Michiel S. Van der Heijden and Dmytro Trukhin and Avivit Peer and Howard Gurney and Boris Y. Alekseev and Francis X. Parnis and Raya Leibowitz and Maria De Santis and Petros Grivas and Jason Clark and Mihaela Munteanu and Ritesh Kataria and Calvin Jia and Arjun V. Balar and Ronald de Wit},
year = {2024},
journal = {BMC Cancer},
doi = {10.1186/s12885-023-10727-3},
url = {https://doi.org/10.1186/s12885-023-10727-3}
}RIS
TY - JOUR TI - Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study AU - Andrea Necchi AU - Michiel S. Van der Heijden AU - Dmytro Trukhin AU - Avivit Peer AU - Howard Gurney AU - Boris Y. Alekseev AU - Francis X. Parnis AU - Raya Leibowitz AU - Maria De Santis AU - Petros Grivas AU - Jason Clark AU - Mihaela Munteanu AU - Ritesh Kataria AU - Calvin Jia AU - Arjun V. Balar AU - Ronald de Wit PY - 2024 JO - BMC Cancer DO - 10.1186/s12885-023-10727-3 UR - https://doi.org/10.1186/s12885-023-10727-3 ER -
APA
Necchi, A., Heijden, M. S. V. D., Trukhin, D., Peer, A., Gurney, H., Alekseev, B. Y., Parnis, F. X., Leibowitz, R., Santis, M. D., Grivas, P., Clark, J., Munteanu, M., Kataria, R., Jia, C., Balar, A. V., & Wit, R. D. (2024). Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. BMC Cancer. https://doi.org/10.1186/s12885-023-10727-3
Source records
- crossref · retrieved 2026-11-10T19:55:45.556Z